Goldline Pharmaceutical Ltd
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]
- Market Cap ₹ 38.9 Cr.
- Current Price ₹ 40.5
- High / Low ₹ 60.0 / 33.0
- Stock P/E 9.44
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 30.6 %
- ROE 39.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%
Cons
- Company has high debtors of 189 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 19.73 | 23.48 | 28.01 | 31.18 | |
| 17.32 | 19.14 | 21.86 | 24.09 | |
| Operating Profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21% | 18.48% | 21.96% | 22.74% |
| -0.20 | -0.04 | -0.09 | 0.00 | |
| Interest | 1.63 | 1.61 | 1.95 | 1.46 |
| Depreciation | 0.18 | 0.16 | 0.25 | 0.24 |
| Profit before tax | 0.40 | 2.53 | 3.86 | 5.39 |
| Tax % | 37.50% | 28.46% | 26.42% | 23.38% |
| 0.26 | 1.81 | 2.83 | 4.12 | |
| EPS in Rs | 1.30 | 7.87 | 4.10 | 5.97 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 119% |
| TTM: | 42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| Last Year: | 39% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2.00 | 2.30 | 6.90 | 6.90 |
| Reserves | 2.08 | 3.76 | 1.55 | 5.54 |
| 12.64 | 12.94 | 12.85 | 10.97 | |
| 2.67 | 3.93 | 4.88 | 5.47 | |
| Total Liabilities | 19.39 | 22.93 | 26.18 | 28.88 |
| 2.50 | 2.95 | 2.89 | 2.71 | |
| CWIP | 0.00 | 0.45 | 0.00 | 0.00 |
| Investments | 0.07 | 0.03 | 0.03 | 0.03 |
| 16.82 | 19.50 | 23.26 | 26.14 | |
| Total Assets | 19.39 | 22.93 | 26.18 | 28.88 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2.39 | 2.92 | 3.18 | 2.81 | |
| -1.04 | -1.11 | 0.16 | -0.06 | |
| -1.44 | -1.08 | -2.89 | -3.40 | |
| Net Cash Flow | -0.09 | 0.74 | 0.45 | -0.65 |
| Free Cash Flow | 1.38 | 1.81 | 3.35 | 2.75 |
| CFO/OP | 101% | 72% | 66% | 53% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 159.65 | 149.54 | 139.30 | 188.82 |
| Inventory Days | 336.20 | 450.39 | 229.14 | 202.38 |
| Days Payable | 54.47 | 98.62 | 69.62 | 60.29 |
| Cash Conversion Cycle | 441.39 | 501.32 | 298.82 | 330.91 |
| Working Capital Days | 143.74 | 132.76 | 133.57 | 156.28 |
| ROCE % | 23.40% | 29.28% | 30.64% |
Insights
In beta| Mar 2018 | Mar 2019 | |
|---|---|---|
| Number of states with presence count |
|
|
| Number of carrying and forwarding agents count |
||
| Number of stockists count |
||
| Promoters' experience in pharmaceutical industry years |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Notice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company.
- Intimation Of Record Date For Remote E-Voting
- Intimation Of Book Closure Shall Remain Closed From Sunday 23Rd August, 2026 To Saturday 29Th August, 2026 (Both Days Inclusive) For Taking Record Of The Members Of The Company For The Purpose Of 22Nd (Twenty Second) Annual General Meeting Of The Company Scheduled To Be Held Saturday 29Th August, 2026 At 04:00 P.M
-
Reg. 34 (1) Annual Report.
- Goldline Pharmaceutical submitted FY2025-26 annual report; AGM on 29 Aug 2026, with dividend and related-party approvals.
-
Intimation Of Notice Of 22Nd Annual General Meeting Of Goldline Pharmaceutical Limited Will Be Held On Saturday, 29Th August, 2026 At 4:00 P.M. At Hotel Airport Centre Point, 131/1, Adjacent To Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025
- 22nd AGM on 29 Aug 2026 to adopt FY26 accounts, declare preference dividend, and approve 200 Cr borrowing resolutions.
Business Profile:[1]
Goldline Pharmaceutical is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand through
an asset-light, third-party manufacturing model. The company does not manufacture products
in-house; instead, it partners with contract manufacturers for production while focusing
on product selection, branding, distribution, marketing, and supply chain management.